Nevertheless, these data demonstrated that JMT101 plus osimertinib has the potential to be a new treatment option for patients with EGFR 20ins-positive NSCLC, especially for those with untreated CNS metastasis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.